Skip to main content

FDA recall, , Moderate risk

Fresenius Medical Care DELFLEX Peritoneal Dialysis Solution

Delflex Peritoneal Dialysis Solution lacks assurance of sterility.

What happened

Fresenius Medical Care, Renal Therapies Group, LLC, of Lawrence, Massachusetts, initiated a voluntary recall of Delflex Peritoneal Dialysis Solution products because of a lack of assurance of sterility. The recall began on October 14, 2026, and was added to the FDA's Enforcement Report on November 2, 2026. The products were distributed nationwide in the USA.

The affected products include Delflex Peritoneal Dialysis Solution with 1.5% Dextrose, 2.5% Dextrose, and 4.25% Dextrose, each with Low Magnesium/ Low Calcium and an Attached stay safe Exchange Set, in 2,000 mL or 2,500 mL single-dose bags. Customers were notified by letter.

3 photos

What to do

The FDA notice gives no instructions for this recall. FDA's general advice for medicine recalls:

  1. Check the FDA or company notice for instructions specific to this product.
  2. Ask your pharmacist or doctor whether your lot is affected and what to do.

Is yours affected?

Compare the details below with your product and check the FDA notice to confirm whether it is affected.

An NDC (National Drug Code) is usually printed on the drug's label.

  1. Product details

    DELFLEX Peritoneal Dialysis Solution with 1.5% Dextrose, Low Magnesium/ Low Calcium and Attached stay safe Exchange Set, 2,000 mL - Single Dose Bag, Sterile and Non-Pyrogenic, Rx only, CAT.NO. 054-20221. Fresenius Medical Care, Renal Therapies Group, LLC, Lawrence, MA 01843

    NDC
    • 46163-206-92
    Lot code
    • 25JGPD045
    • 25JGPD046
    • 25JGPD060
    • 25KGPD057
  2. Product details

    DELFLEX Peritoneal Dialysis Solution with 4.25% Dextrose, Low Magnesium/ Low Calcium and Attached stay safe Exchange Set, 2,500 mL Single dose bag, Sterile and Non-Pyrogenic, Rx only, CAT.NO. 054-25324. Fresenius Medical Care, Renal Therapies Group, LLC, Lawrence, MA 01843

    NDC
    • 46163-212-94
    Lot code
    • 25NGPD001
  3. Product details

    DELFLEX Peritoneal Dialysis Solution with 2.5% Dextrose, Low Magnesium/ Low Calcium and Attached stay"safe Exchange Set, 2,500 mL Single dose bag, Sterile and Non-Pyrogenic, Rx only, CAT. NO. 054-25322. Fresenius Medical Care, Renal Therapies Group, LLC, Lawrence, MA 01843

    NDC
    • 46163-209-94
    Lot code
    • 25JGPD069
    • 25SGPD046
    • 25SGPD059
    • 25SGPD063
    • 26EGPD022
  4. Product details

    DELFLEX Peritoneal Dialysis Solution with 2.5% Dextrose, Low Magnesium/ Low Calcium and Attached stay safe Exchange Set, 2,000 mL Single dose bag, Sterile and Non-Pyrogenic, Rx only, CAT. No. 054-20222. Fresenius Medical Care, Renal Therapies Group, LLC, Lawrence, MA 01843

    NDC
    • 46163-209-92
    Lot code
    • 25DGPD002
    • 25DGPD003
    • 25KGPD027
    • 25KGPD042
    • 25SGPD033
    • 26AGPD033
    • 26AGPD054
  5. Product details

    DELFLEX Peritoneal Dialysis Solution with 1.5% Dextrose, Low Magnesium/ Low Calcium and Attached stay safe Exchange Set, 2,500 mL Single dose bag, Sterile and Non-Pyrogenic, Rx only, CAT. NO. 054-25321. Fresenius Medical Care, Renal Therapies Group, LLC, Lawrence, MA 01843

    NDC
    • 46163-206-94
    Lot code
    • 25HGPD037
    • 26CGPD074

Recall details

Posted by FDA
Recall began
Status
Open
Sold in

Nationwide in the USA.

Recalled by
NxStage Medical IncLawrence, Massachusetts
Risk

Moderate risk

Taking it may cause short-term health problems, or ones that treatment can reverse. Serious harm is unlikely.

FDA Class II recall · How risk is rated

FDA event number
100130
Recall numbers
D-0167-2027 to D-0171-2027
Recall type
Voluntary: Firm initiated
How the company first told customers
Letter

All recalls from NxStage Medical Inc

Timeline

FDA's Enforcement Report is its public list of recalls; FDA posts a recall by adding it there.

  1. NxStage Medical began the recall

  2. FDA posted the recall to its Enforcement Report

  3. FDA rated the recall Class II (moderate risk) · Added to Recall Canary

  4. Summary updated

Summary by Recall Canary, written with AI · summary updated Nov 4, 2026 · primary source: U.S. Food and Drug Administration (opens in a new tab)